Cardiff Oncology CEO granted 600,000 stock options

Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock.

Rhea-AI Filing Summary

Cardiff Oncology, Inc. reported that Chief Executive Officer Mani Mohindru received a grant of stock options covering 600,000 shares of common stock. These options have an exercise price of $1.62 per share and expire on March 31, 2036.

The grant is compensation-related, not an open-market trade. Following this award, the filing shows option holdings of 968,766 stock options. A footnote states that 150,000 options vest on March 31, 2027, with 12,500 options vesting monthly for 36 months thereafter, creating a multi-year vesting schedule.

Insights

Equity Compensation Analyst

CEO receives a sizable time-vested option grant, a routine pay mechanism.

The CEO of Cardiff Oncology, Mani Mohindru, was granted stock options over 600,000 shares at an exercise price of $1.62 per share, expiring on March 31, 2036. This is classified as a grant or award, not a market purchase.

A footnote explains that 150,000 options vest on March 31, 2027, with 12,500 vesting monthly for the next 36 months, tying value to continued service. After this grant, option holdings reported total 968,766 options. As a compensation event without any sales, it is a neutral development for existing shareholders.

Insider Trade Summary

Grant/Award: 600,000 shares

Grant/Award 1 txn

Insider Mohindru Mani

Role Chief Executive Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	600,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 968,766 contracts (Direct)

Footnotes (1)

1. F1. 150,000 vest on March 31, 2027 and 12,500 vest monthly for 36 months thereafter

Key Figures

Option Grant Size: 600,000 options Exercise Price: $1.62 per share Expiration Date: March 31, 2036 +3 more

6 metrics

Option Grant Size 600,000 options Stock options over common stock granted to CEO

Exercise Price $1.62 per share Exercise price of granted stock options

Expiration Date March 31, 2036 Option expiration for this grant

Options After Grant 968,766 options Total option holdings following transaction

Initial Vesting Tranche 150,000 options Vests on March 31, 2027 per footnote

Monthly Vesting Amount 12,500 options Vest monthly for 36 months after March 31, 2027

Key Terms

Stock Options, grant/award acquisition, exercise price, vesting

4 terms

Stock Options financial

"security_title: "Stock Options" and underlying security labeled Common Stock"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

grant/award acquisition financial

"transaction_action: "grant/award acquisition" for the CEO option grant"

exercise price financial

"conversion_or_exercise_price set at 1.6200 per share for the options"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"footnote: "150,000 vest on March 31, 2027 and 12,500 vest monthly""

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cardiff Oncology (CRDF) CEO Mani Mohindru report in this Form 4?

The Form 4 shows CEO Mani Mohindru received a grant of stock options for 600,000 shares at a $1.62 exercise price. The options are compensation-related, not an open-market trade, and increase her potential future equity exposure if exercised.

How many stock options did the Cardiff Oncology (CRDF) CEO receive and at what price?

The CEO was granted stock options covering 600,000 shares of Cardiff Oncology common stock with an exercise price of $1.62 per share. These options provide the right, but not obligation, to buy shares at that price before expiration.

What is the vesting schedule for the new Cardiff Oncology (CRDF) stock options?

A footnote states that 150,000 options vest on March 31, 2027, and 12,500 additional options vest monthly for 36 months thereafter. This structure encourages long-term alignment by spreading vesting over several years of continued employment.

When do the newly granted Cardiff Oncology (CRDF) stock options expire?

The stock options granted to the CEO expire on March 31, 2036. After that date, any unexercised options will lapse and can no longer be used to purchase Cardiff Oncology common stock at the $1.62 exercise price.

Did the Cardiff Oncology (CRDF) CEO buy or sell shares on the market in this filing?

No market buy or sell occurred. The Form 4 reports an “A” code grant, meaning the CEO received stock options as a grant or award. It reflects equity compensation, not an open-market stock transaction with outside investors.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/02/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohindru Mani

(Last) (First) (Middle)

11055 FLINTKOTE AVENUE

C/O CARDIFF ONCOLOGY, INC.

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$1.62	03/31/2026		A		600,000		(1)	03/31/2036	Common Stock	600,000	$0	968,766	D

Explanation of Responses:

1. 150,000 vest on March 31, 2027 and 12,500 vest monthly for 36 months thereafter

	/s/ Mani Mohindru	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)